All articles tagged with #drug combination
A study finds that combining the drugs silybin and carvedilol produces a strong synergistic effect in reversing liver fibrosis by inhibiting scar tissue formation, offering a promising new treatment approach using existing, safe medications.
A Phase III trial found that adding niraparib, a PARP inhibitor, to standard treatment significantly delays progression of advanced prostate cancer in men with specific DNA repair gene mutations, suggesting a promising personalized therapy approach, despite some increased side effects.
Pharma companies Pfizer, Merck, and Astellas reported promising results from a study showing that their drug combination of Padcev and Keytruda significantly extends survival and reduces recurrence in muscle-invasive bladder cancer patients, offering new hope for treatment options.
European scientists have found that a combination of two cancer drugs, rapamycin and trametinib, can extend mice lifespans by up to 30% and improve their health, with potential implications for human aging and age-related diseases.
A new drug combination of avutometinib and defactinib is showing promising results in treating low-grade serious ovarian cancer, with nearly half of the patients experiencing significant tumor shrinkage. The clinical trial results are particularly significant for younger women who are afflicted with this type of cancer.
A new drug combination has shown promising results in shrinking tumours in almost half of patients with low-grade serous ovarian cancer, according to clinical trial results presented at the American Society of Clinical Oncology’s annual meeting. The drug combination, which includes avutometinib and defactinib, was found to be almost twice as effective as the next best treatment option. The treatment blocks tumour growth and could represent a significant breakthrough for women with low-grade serous ovarian cancer, which tends to affect younger women.
Pfizer and Astellas have reported that their drug Xtandi, in combination with leuprolide, reduces the risk of metastasis and death in prostate cancer by 58%. The Phase III EMBARK trial tested Xtandi plus leuprolide and Xtandi as a monotherapy against placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. The companies believe that the data shows the potential for Xtandi to be added to the standard of care if a label expansion is approved.